Amgen Research (munich) Gmbh

Bayerische Motoren Werke Aktiengesellschaft

Micromet Ag

Amgen Inc.

Claudius Peters Projects Gmbh

Amgen Research Gmbh

Andreas Wolf

Tobias Raum

Peter Kufer

Patrick Hoffmann

Benno Rattel

Cornelius Pompe

Johannes Brozy

Matthias Friedrich

Markus Münz

Pamela Bogner

Jan Danneberg

Juergen Leschhorn

Steven Zeman

Sandra Bruckmaier

Patrick A Baeuerle

Sonja Offner

Birgit Kohleisen

Doris Rau

Robert Hofmeister

Elisabeth Nahrwold

Christoph Dahlhoff

Ronny Grosse

Jochen Pendzialek

Ulla Lenkkeri-Schütz

Markus Amsz

Meera Berry

Klaus Brischwein

Eva Krinner

Silke Mittelstrass

Julia Henckel

Eva Vieser (nee Krinner)

Silke Petsch (nee Mittelstrass)

Julia Hepp (nee Henckel)

Patrick Bäuerle

Peter Hilgraf

Christian Itin

Markus Muenz

Ines Herrmann

Thomas Urbig

Julie Bailis

Jonas Anlahr

Michael Kreitz

Andre Heckert

Martin Gamboni

Nadja Prang

Julia Hepp

Claudia Bluemel

Frank Hanakam

Eva Vieser

Silke Petsch

Franziska Bott

Michael Altmann-Rinck

Patrick Bauerle

Ulla Lenkkeri-Schutz

Patrick Baeuerle

The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to PSMA, a second domain binding to an extracellular epitope of the human and theCD3ε chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.

PSMA and CD3 bispecific T cell engaging antibody constructs

A body for an electrically operable motor vehicle, includes a vehicle floor, which has a floor element arranged above an energy storage device and, in the region of the end of the floor element, at least one fastening point of the body for a support element is provided. In the event of an accident-induced load introduction of a corresponding force in the region of the fastening point, in order to prevent accompanying damage to the energy storage device, the floor element has a deformation region that can be intentionally deformed away from the energy storage device when the accident-induced force is introduced at the fastening point of the body for the support element.

Body for an electrically operable motor vehicle

An energy store-floor assembly for a motor vehicle includes an electrical energy storage device that has a plurality of battery modules and that is accommodated in a multipart storage housing and arranged on the underside of a vehicle floor of the motor vehicle. In order to provide an energy store-floor assembly for a motor vehicle in which the energy storage device is connected to the motor vehicle bodyshell in an improved manner, the battery modules of the energy storage device are connected to the vehicle floor in a central region of the storage housing by way of a plurality of mechanical connecting elements.

Energy store-floor assembly for a motor vehicle

An energy-store floor assembly for a motor vehicle includes an electrical energy-store device which has a plurality of battery modules and is accommodated in a multi-part store housing and arranged on the bottom side of a vehicle floor of the motor vehicle. In order that the store housing can be adapted to the shape of the motor vehicle body and/or to components of the energy-store device in an improved way, housing parts of the store housing are interconnected by at least one gas-tight connection, which has an uneven course with respect to the vehicle vertical direction in at least one length region.

Energy-store floor assembly for a motor vehicle

The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to a target cell surface antigen, a second domain binding to an extracellular epitope of the human and/or theCD3&#x3b5; chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.

Bispecific T cell engaging antibody constructs

The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to BCMA, a second domain binding to an extracellular epitope of the human and/or theCD3&#x3b5; chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.

BCMA and CD3 bispecific T cell engaging antibody constructs

The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to PSMA, a second domain binding to an extracellular epitope of the human and theCD3&#x3b5; chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.

The present invention relates to a human monoclonal antibody or fragment thereof which specifically binds to and neutralizes primate GM-CSF.

Antibody neutralizers of human granulocyte macrophage colony stimulating factor

The present invention relates to compositions comprising polypeptides, especially polypeptides capable of specifically binding predetermined antigens. The polypeptide in the composition comprises at least two antigen binding sites. These at least two antigen binding sites are located on a single polypeptide chain. One of the at least two antigen binding sites specifically binds the human CD3 antigen. The polypeptide may exist in both monomeric form and multimeric form. The multimeric form of the polypeptide constitutes no more than 5% of the total weight of the combined monomeric and multimeric forms of said polypeptide.

Compositions comprising polypeptides

The invention relates to methods of preparing antibody fragments. The invention further relates to antibody fragments prepared by these methods. The invention further relates to antibody variable regions comprised in antibody fragments producible by these methods.

Preparation of scFv antibody fragments

The present invention provides a pharmaceutical composition comprising a bispecific single chain antibody construct. Said bispecific single chain antibody construct is characterized to comprise or consist of at least two domains, whereby one of said at least two domains specifically binds to human EpCAM and comprises at least one CDR-H3 region comprising the amino acid sequence NXID antigen and a second domain binds to human CD3 antigen. The invention further provides a process for the production of the pharmaceutical composition of the invention, a method for the prevention, treatment or amelioration of a tumorous disease and the use of the disclosed bispecific single chain antibody construct and corresponding means in the prevention, treatment or amelioration of a tumorous disease.

Pharmaceutical composition comprising a bispecific antibody for EpCAM

The invention relates to methods of preparing antibody fragments. The invention further relates to antibody fragments prepared by said methods. The invention further relates to antibody variable regions comprised in antibody fragments producible by said methods.

Growing community of inventors

Munich, Germany

Andreas Wolf